Every 8-K that Beam Therapeutics Inc. (BEAM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BEAM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEAM filings page.
Beam Therapeutics Inc. reported results for the quarter ended June 30, 2026 and highlighted significant clinical milestones across its base-editing portfolio. License and collaboration revenue was $490 thousand. The company reported a net loss of $122.7 million, or $1.18 per share, and ended the quarter with $1.2 billion in cash, cash equivalents and marketable securities.
Beam expects its June 30, 2026 cash balance, together with $200 million expected from a credit facility with Sixth Street, to fund operations into mid-2029. Clinically, the first patient was dosed in the global pivotal cohort of the BEAM-302 AATD trial, dosing was completed in the BEACON risto-cel SCD trial with a planned BLA submission as early as year-end 2026, and the FDA cleared the IND for BEAM-304 in PKU. BEAM-301 continues in a Phase 1/2 GSDIa trial with initial data expected in 2026.
Beam Therapeutics Inc. reported results from its 2026 annual meeting of stockholders held on June 3, 2026. Stockholders elected Class III directors John Evans, John Maraganore, Ph.D., and Christi Shaw to serve until the 2029 annual meeting, with each nominee receiving over 64.8 million votes in favor and substantial broker non-votes.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 85.75 million votes for and minimal opposition. In addition, they approved, on an advisory basis, the compensation of the company’s named executive officers, with approximately 71.5 million votes for and relatively low opposition and abstentions.
Beam Therapeutics reported first quarter 2026 results alongside major clinical milestones. License and collaboration revenue rose to $31.7 million, up from $7.5 million a year earlier, while net loss narrowed to $94.3 million or $0.91 per share. Cash, cash equivalents and marketable securities totaled $1.2 billion as of March 31, 2026, supporting a projected cash runway into mid-2029.
Clinically, updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency showed rapid, durable increases in total and functional AAT and a well‑tolerated safety profile, leading Beam to select 60 mg as the optimal biological dose and plan a pivotal expansion cohort in the second half of 2026 under an accelerated approval pathway. In sickle cell disease, Phase 1/2 BEACON data for risto-cel were published in The New England Journal of Medicine, and Beam expects to submit a biologics license application as early as year‑end 2026.
Beam also plans an IND filing for BEAM-304 in phenylketonuria and initial 2026 data for BEAM-301 in glycogen storage disease type Ia, while an ongoing healthy volunteer trial of BEAM-103 is expected to complete dosing in the first half of 2026.
Beam Therapeutics Inc. terminated its 2019 cross-license agreement with Bio Palette Co., Ltd. as of March 2, 2026, in connection with Bio Palette’s planned dissolution. That agreement had given Beam exclusive, royalty-bearing rights to certain base editing patents for treating human disease worldwide, excluding microbiome products in Asia, while Beam granted Bio Palette exclusive, royalty-bearing rights to use certain Beam base and gene editing patents in the microbiome field in Asia.
Before this termination, Bio Palette and Kobe University ended their own license, which activated a previously arranged standby license between Beam and Kobe. Under this standby license, Kobe directly provides Beam an exclusive license, of the same scope as the original Bio Palette license, to practice specified patents. All rights and licenses between Beam and Bio Palette have now ended, the parties granted each other a mutual release of claims, and no further payments are owed between Beam and Bio Palette under either the termination agreement or the prior license.
Beam Therapeutics entered a senior secured term loan facility of up to $500 million with Sixth Street, providing long-term, largely non-dilutive capital to support risto-cel and other programs. The credit facility includes $100 million funded at closing and additional potential tranches tied to FDA and revenue milestones, matures in 2033, and bears interest at 3‑month SOFR plus 6.50% with a 1.00% floor.
The company reported strong fourth-quarter 2025 results, driven by license and collaboration revenue of $114.1 million and a $255.1 million gain on sale of an equity method investment, resulting in net income of $244.3 million or $2.37 per basic share. Cash, cash equivalents and marketable securities were $1.25 billion as of December 31, 2025, and, together with at least $200 million expected from the facility, are projected to fund operations into mid‑2029.
Beam also expanded its liver-targeted franchise with BEAM‑304 for phenylketonuria, aiming for an IND filing in 2026, advanced BEAM‑302 in alpha‑1 antitrypsin deficiency under an FDA-aligned accelerated approval plan, and reiterated plans to submit a BLA for risto‑cel in sickle cell disease as early as year-end 2026.
Beam Therapeutics Inc. entered into a standby license agreement with Kobe University and Bio Palette Co., Ltd. to protect its access to certain licensed patents if the existing Kobe-Bio Palette License ends. If that license terminates under specified conditions, Kobe will grant Beam an exclusive license to practice the same patents and scope it currently accesses through Bio Palette. After the termination becomes effective, Beam will make payments to Kobe in amounts that would otherwise become payable to Bio Palette under the existing Bio Palette-Beam License. This structure is designed to ensure continuity of Beam’s patent rights around its licensed technology.
Beam Therapeutics Inc. reported that Carole Ho has submitted her resignation from the company’s Board of Directors. Her resignation is effective February 27, 2026, giving the company a short transition period to adjust its board composition.
The company states that Dr. Ho’s decision to resign did not result from any disagreement regarding Beam’s operations, policies, or practices. This indicates a voluntary board change rather than a response to a dispute or governance conflict.
Beam Therapeutics Inc. reported in a current update that it estimates having approximately $1.25 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is preliminary, unaudited and may change as the company completes its year-end closing and prepares full financial statements, so the company cautions against placing undue reliance on the estimate.
Beam also highlighted progress across its base editing portfolio and described key anticipated milestones in a press release and updated corporate presentation furnished as exhibits. These materials will support upcoming conference appearances, including an investor presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Beam Therapeutics furnished a Form 8-K to announce its financial results for the quarter ended September 30, 2025.
The company issued a press release, furnished as Exhibit 99.1. The information in Item 2.02 and Exhibit 99.1 is furnished and is not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
Report type: Current Report on Form 8-K dated August 5, 2025 by Beam Therapeutics Inc. (BEAM).
On August 5, 2025 the Company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The filing states that the information and Exhibit 99.1 are being furnished (not "filed") for purposes of the Exchange Act and are not subject to Section 18 liability except by specific reference.
Corporate details: Beam Therapeutics Inc., Delaware, principal office 238 Main Street, Cambridge, MA 02142; common stock trades as BEAM on Nasdaq Global Select Market. Form signed by John Evans, Chief Executive Officer.